Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Opioid Use Disorder (OUD) Market, by Drug Class
1.4.2 Europe Opioid Use Disorder (OUD) Market, by Route of Administration
1.4.3 Europe Opioid Use Disorder (OUD) Market, by Distribution Channel
1.4.4 Europe Opioid Use Disorder (OUD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market
Chapter 4. Europe Opioid Use Disorder (OUD) Market by Drug Class
4.1 Europe Buprenorphine Market by Country
4.2 Europe Methadone Market by Country
4.3 Europe Naltrexone Market by Country
Chapter 5. Europe Opioid Use Disorder (OUD) Market by Route of Administration
5.1 Europe Parenteral Market by Country
5.2 Europe Oral Market by Country
Chapter 6. Europe Opioid Use Disorder (OUD) Market by Distribution Channel
6.1 Europe Hospital Pharmacies Market by Country
6.2 Europe Retail Pharmacies & Stores Market by Country
6.3 Europe Online Pharmacies Market by Country
Chapter 7. Europe Opioid Use Disorder (OUD) Market by Country
7.1 Germany Opioid Use Disorder (OUD) Market
7.1.1 Germany Opioid Use Disorder (OUD) Market by Drug Class
7.1.2 Germany Opioid Use Disorder (OUD) Market by Route of Administration
7.1.3 Germany Opioid Use Disorder (OUD) Market by Distribution Channel
7.2 UK Opioid Use Disorder (OUD) Market
7.2.1 UK Opioid Use Disorder (OUD) Market by Drug Class
7.2.2 UK Opioid Use Disorder (OUD) Market by Route of Administration
7.2.3 UK Opioid Use Disorder (OUD) Market by Distribution Channel
7.3 France Opioid Use Disorder (OUD) Market
7.3.1 France Opioid Use Disorder (OUD) Market by Drug Class
7.3.2 France Opioid Use Disorder (OUD) Market by Route of Administration
7.3.3 France Opioid Use Disorder (OUD) Market by Distribution Channel
7.4 Russia Opioid Use Disorder (OUD) Market
7.4.1 Russia Opioid Use Disorder (OUD) Market by Drug Class
7.4.2 Russia Opioid Use Disorder (OUD) Market by Route of Administration
7.4.3 Russia Opioid Use Disorder (OUD) Market by Distribution Channel
7.5 Spain Opioid Use Disorder (OUD) Market
7.5.1 Spain Opioid Use Disorder (OUD) Market by Drug Class
7.5.2 Spain Opioid Use Disorder (OUD) Market by Route of Administration
7.5.3 Spain Opioid Use Disorder (OUD) Market by Distribution Channel
7.6 Italy Opioid Use Disorder (OUD) Market
7.6.1 Italy Opioid Use Disorder (OUD) Market by Drug Class
7.6.2 Italy Opioid Use Disorder (OUD) Market by Route of Administration
7.6.3 Italy Opioid Use Disorder (OUD) Market by Distribution Channel
7.7 Rest of Europe Opioid Use Disorder (OUD) Market
7.7.1 Rest of Europe Opioid Use Disorder (OUD) Market by Drug Class
7.7.2 Rest of Europe Opioid Use Disorder (OUD) Market by Route of Administration
7.7.3 Rest of Europe Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Indivior PLC (Reckitt Benckiser Group plc)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Product and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Orexo AB (Orexo US, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Alkermes PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.5 Titan Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Trials and Approvals:
8.6 Camurus AB
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Trials and Approvals:
8.7 AstraZeneca PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Hikma Pharmaceuticals PLC
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Product Launches and Product Expansions:
8.9 Mallinckrodt PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Viatris, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental Analysis
8.10.4 Research & Development Expense
Unique Offerings 